Survival of Patients with Primary Cardiac Tumors in an 11-Year Single Center Study
Survival of primary cardiac tumors
Background: Primary cardiac tumors are rare, but few studies have examined the relationship between risk factors and the prognosis. The aim of this study was to provide a survival analysis and risk factors for mortality in patients with primary cardiac tumors.
Methods: We retrospectively enrolled 71 patients diagnosed with primary cardiac tumors from June 2006 to November 2017 in our hospital. Patients’ population characteristics, treatment information, pathology, and follow-up data were obtained and analyzed.
Results: Of the 71 patients, 60 cases were benign, and 11 cases were malignant. Sex, age, New York Heart Association classification, the percentage of peripheral embolism, and surgery had no significant difference between benign and malignant groups (P >.05), but the percentage of arrhythmia, leg edema, and mortality rate was higher in the malignant tumor group than in the benign tumor group (P <.05). Compared with the benign tumor group, the percentage of biatrial lesions in the malignant tumor group was significantly higher (P <.05). Moreover, Independent risk factors included the treatment choice, pathology type, and number of tumor lesions (P <.05).
Conclusion: Our study suggests that conservative therapy, malignant cardiac tumor, and biatrial tumor lesion are independent risk factors for poor prognosis.
Bakaeen FG, Reardon MJ, Coselli JS, et al. 2003. Surgical outcome in 85 patients with primary cardiac tumors. Am J Surg 186(6):641-7; discussion 647.
Barnes H, Conaglen P, Russell P, Newcomb A. 2014. Clinicopathological and surgical experience with primary cardiac tumors. Asian Cardiovasc Thorac Ann 22(9):1054-8.
Barreiro M, Renilla A, Jimenez JM, et al. 2013. Primary cardiac tumors: 32 years of experience from a Spanish tertiary surgical center. Cardiovasc Pathol 22(6):424-7.
Bossert T, Gummert JF, Battellini R, et al. 2005. Surgical experience with 77 primary cardiac tumors. Interact Cardiovasc Thorac Surg 4(4):311-5.
Butany J, Nair V, Naseemuddin A, Nair GM, Catton C, Yau T. 2005. Cardiac tumours: diagnosis and management. Lancet Oncol 6(4):219-28.
Chitwood WR Jr. 1992. Clarence Crafoord and the first successful resection of a cardiac myxoma. Ann Thorac Surg 54(5):997-8.
Dias RR, Fernandes F, Ramires FJA, Mady C, Albuquerque CP, Jatene FB. 2014. Mortality and embolic potential of cardiac tumors = Mortalidade e potencial embólico dos tumores cardíacos. Arq Bras Cardiol 103(1):13-8. English, Portuguese.
Habertheuer A, Laufer G, Wiedemann D, et al. 2015. Primary cardiac tumors on the verge of oblivion: a European experience over 15 years. J Cardiothorac Surg 10:56.
Hoffmeier A, Sindermann JR, Scheld HH, Martens S. 2014. Cardiac tumors--diagnosis and surgical treatment. Dtsch Arztebl Int 111(12):205-11.
Kośmider A, Jaszewski R, Marcinkiewicz A, Bartczak K, Knopik J, Ostrowski S. 2013. 23-year experience on diagnosis and surgical treatment of benign and malignant cardiac tumors. Arch Med Sci 9(5):826-30.
Li S, Gao C. 2017. Surgical experience of primary cardiac tumor: single-institution 23-year report. Med Sci Monit 23:2111-7.
Mkalaluh S, Szczechowicz M, Torabi S, et al. 2017. Surgical treatment of cardiac tumors: insights from an 18-year single-center analysis. Med Sci Monit 23:6201-9.
Nomoto N, Tani T, Konda T, et al. 2017. Primary and metastatic cardiac tumors: echocardiographic diagnosis, treatment and prognosis in a 15-years single center study. J Cardiothorac Surg 12(1):103.
Oliveira GH, Al-Kindi SG, Hoimes C, Park SJ. 2015. Characteristics and survival of malignant cardiac tumors: a 40-year analysis of >500 patients. Circulation 132(25):2395-402.
Roberts WC. 1997. Primary and secondary neoplasms of the heart. Am J Cardiol 80(5): 671-82.
Saad AM, Abushouk AI, Al-Husseini MJ, et al. 2018. Characteristics, survival and incidence rates and trends of primary cardiac malignancies in the United States. Cardiovasc Pathol 33:27-31.
Simpson L, Kumar SK, Okuno SH, et al. 2008. Malignant primary cardiac tumors: review of a single institution experience. Cancer 112(11):2440-6.
Strecker T, Rösch J, Weyand M, Agaimy A. 2012. Primary and metastatic cardiac tumors: imaging characteristics, surgical treatment, and histopathological spectrum: a 10-year-experience at a German heart center. Cardiovasc Pathol 21(5):436-43.
Yin L, He D, Shen H, et al. 2016. Surgical treatment of cardiac tumors: a 5-year experience from a single cardiac center. J Thorac Dis 8(5):911-9.
Yu L, Gu T, Shi E, et al. 2014. Primary malignant cardiac tumors. J Cancer Res Clin Oncol 140(6):1047-55.
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).